Refractory angina (RA) presents a unique and frustrating challenge in cardiovascular care. Despite optimal medical therapy and advanced revascularization strategies, a significant number of patients continue to experience debilitating ischemic chest pain. For cardiovascular physiotherapists, determining the safest and most effective way to prescribe exercise for this demographic has historically been clouded by a lack of robust clinical evidence. The inherent fear of triggering severe adverse cardiovascular events often limits the application of structured exercise-based cardiac rehabilitation (ECR). However, a recent 2025 prospective, single-center, randomized controlled trial sheds highly anticipated light on the safety, efficacy, and anti-ischemic benefits of ECR for this specific, high-risk population.
Evaluating a 12-Week Cardiac Rehabilitation Protocol
To address the existing clinical evidence gap, researchers conducted a rigorous randomized controlled trial focusing on the safety and efficacy of a 12-week ECR program tailored for patients with RA. Forty-five patients were randomized into two distinct groups: a rehabilitation group that participated in the structured ECR program alongside standard medical treatment, and a control group that received medical treatment alone. To comprehensively assess the outcomes, the research team meticulously monitored mortality, major cardiovascular events, and subjective anginal symptoms. Crucially, they utilized advanced diagnostics, including exercise stress echocardiography (ESE) and cardiopulmonary exercise testing (CPET), to accurately measure objective changes in functional capacity and ischemic burden over the three-month period.
Significant Reductions in Ischemic Burden and Symptom Severity
The clinical outcomes of the 12-week intervention strongly advocate for the integration of structured, supervised exercise into the comprehensive management of refractory angina. According to ESE results, patients in the rehabilitation group demonstrated a significantly greater exercise duration post-intervention compared to their baseline metrics. Most notably, the quantification of angina was substantially lower in the ECR group compared to both their pre-intervention baseline and the control group. The physical threshold at which patients experienced angina also increased significantly, effectively allowing them to engage in more daily physical activity before the onset of limiting symptoms.
Furthermore, the trial revealed a marked, objective improvement in the ischemic burden. ESE data showed an increased time to the ischemic threshold for those who successfully completed the cardiac rehabilitation program. During cardiopulmonary exercise testing, the rehabilitation group not only prolonged their overall exercise duration but also significantly increased the total distance covered. Interestingly, no significant differences in peak VO2 were observed between the two groups, yet the functional and symptomatic improvements in the ECR cohort were undeniable and clinically meaningful.
Safety Profile and Clinical Takeaways for Physiotherapists
Patient safety remains the paramount concern when prescribing exercise for populations with refractory angina. This RCT provides highly reassuring data: there were no significant differences in major cardiovascular events between the exercising and non-exercising groups. While two patients in the medically-managed control group passed away, only one patient in the rehabilitation group experienced an episode of prolonged angina during an exercise training session. This strongly indicates that a closely monitored, expertly prescribed 12-week ECR program is not only highly effective but fundamentally safe.
For physiotherapy professionals, these findings are paradigm-shifting. Structured cardiovascular rehabilitation should not be unnecessarily withheld from patients with RA out of an abundance of caution. Instead, with appropriate initial screening, careful monitoring, and supervised progression, ECR serves as a critical, evidence-based tool to enhance functional capacity, elevate the angina threshold, and ultimately improve the daily quality of life for patients burdened by chronic, treatment-resistant ischemia.
References
Dourado, L. O. C., Jordão, C. P., Vieira, M. L. C., Gowdak, L. H. W., Negrão, C. E., Cesar, L. A. M., & Matos, L. D. N. J. (2025). Safety and Efficacy of Exercise-based Cardiac Rehabilitation in Patients with Refractory Angina. Arquivos brasileiros de cardiologia. https://pubmed.ncbi.nlm.nih.gov/41637323/
